Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
Status:
Completed
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how
Fiasp® works in a closed-loop system and to determine if any changes need to be made to the
670G pump to optimize the use of Fiasp®.